摘要
目的:研究吡咯-咪唑聚酰胺(PIP)对凝集素样氧化型低密度脂蛋白受体-1(LOX-1)受体启动子基因的调控,并探讨其对抗大鼠肾脏损害的作用。方法:雄性SD大鼠50只,按随机数字法将大鼠分为五组,每组10只。A组:普通饲料,未用PIP。B组:高脂饲料(含3%胆固醇+10%猪油),未用PIP。C组:高脂饲料,PIP干预组,C1组按10μg/(kg·d)静脉注射;C2组按5μg/(kg·d)静脉注射。D组:高脂饲料,他汀干预组,瑞舒伐他汀5 mg/(kg·d)灌胃给药。治疗时间均为8周。检测肾组织LOX-1 m RNA、MMP-9 m RNA表达水平,测定血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)含量,测定24 h尿蛋白定量、血尿素氮(BUN)和肌酐(Scr)水平。结果:C1组、C2组大鼠肾组织LOX-1 m RNA、MMP-9 m RNA表达水平均较B组低,差异均有统计学意义(P<0.01);C1组、C2组大鼠血清TC、TG、HDL-C、LDL-C水平与B组比较差异均无统计学意义(P>0.05);C1组、C2组大鼠24 h尿蛋白定量较B组明显降低(P<0.01),而血BUN、Scr水平与A组比较差异均无统计学意义(P>0.05)。结论:PIP化合物能明显下调高脂血症大鼠肾组织LOX-1 m RNA表达,改善肾功能及抑制肾脏损害。
Objective：To explore the regulative effects of pyrrole-imidazole polyamide （PIP） on the lectin-like oxidized Low-density lipoprotein receptor-1（LOX-1）receptor gene promoter,and to analyze the effects of PIP on the rat renal injury.Method：The 50 male Sprague Dawley rats were randomly divided into five groups with 10 rats in each group：group A,normal diet,no PIP;group B,high-fat diet,no PIP;group C1, high-fat diet,PIP 10 μg/（kg·d）i.v.;group C2, high-fat diet,PIP 5 μg /（kg·d）i.v.;group D,high-fat diet,rosuvastatin 5 mg/（kg·d）intragastric administration.At the 8th week,the mRNA expressions of LOX-1 and MMP-9 in renal tissue were detected by real-time PCR. The levels of serum cholesterol （TC）,triglycefide （TG）,HDL-C and LDL-C were measured.The 24 hour urine protein excretion,serum BUN and Scr were measured.Result：Compared with group B,the mRNA expressions of LOX-1 and MMP-9 were significantly decreased in the rat kidney of group C1 and C2（P〈0.01）.Compared with group B,the serum TC,TG,HDL-C and LDL-C had no statistical differences in group C1 or C2（P〉0.05）.Compared with group B,the levels of 24 hour urine protein excretion were significantly decreased in the rats of group C1 and C2（P〈0.01）,but the serum BUN and Scr had no statistical differences compared with group A（P〉0.05）.Conclusion：The expression of LOX-1 mRNA was significantly decreased by the PIP in the kidney of high-fat diet rats,which may be involved in the inhibition of the renal injury.
出处
《中国医学创新》
CAS
2016年第23期17-20,共4页
Medical Innovation of China
基金
福建省医学创新课题资助(2012-CX-19)
